Please wait...


Generic Name: pazopanib (paz OH pa nib)
Brand Names: Votrient
Votrient is used to treat renal cell carcinoma (kidney cancer). Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Votrient

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Votrient (pazopanib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Votrient is used to treat advanced renal cell carcinoma (kidney cancer). Votrient is also used to treat soft tissue sarcoma (a tumor that can develop in or around muscles, tendons, joints, organs, or blood vessels). Votrient is usually given after other cancer medications have been tried without successful treatment of soft tissue sarcoma. You should not use Votrient if you have severe liver disease. Learn more

Votrient Side Effects

Votrient Side Effects

Note: This document contains side effect information about pazopanib. Some of the dosage forms listed on this page may not apply to the brand name Votrient.

In Summary

Common side effects of Votrient include: bleeding tendency disorder, abdominal pain, decreased serum glucose, decreased serum magnesium, decreased serum phosphate, diarrhea, fatigue, hypertension, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, increased serum bilirubin, leukopenia, nausea, neutropenia, thrombocytopenia, vomiting, and anorexia. Other side effects include: hypothyroidism, and proteinuria. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to pazopanib: oral tablet


Oral route (Tablet)

Severe and fatal hepatotoxicity has occurred during clinical trials. Monitor hepatic function in all patients. Interrupt, reduce, or discontinue treatment as recommended.

Along with its needed effects, pazopanib (the active ingredient contained in Votrient) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pazopanib:

More common

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • chest pain
  • chills
  • clay colored stools
  • cloudy urine
  • constipation
  • cough
  • coughing up blood
  • dark urine
  • decreased appetite
  • depressed mood
  • difficulty with breathing or swallowing
  • dizziness
  • dry skin and hair
  • feeling cold
  • fever
  • hair loss
  • headache
  • hoarseness or husky voice
  • increased menstrual flow or vaginal bleeding
  • itching, skin rash
  • loss of appetite
  • lower back or side pain
  • muscle cramps and stiffness
  • nausea and vomiting
  • nervousness
  • nosebleeds
  • painful or difficult urination
  • pale skin
  • paralysis
  • pinpoint red spots on the skin
  • pounding in the ears
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark brown urine
  • redness, swelling, or pain of the skin
  • scaling of the skin on the hands and feet
  • slow or fast heartbeat
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • stomach pain or tenderness
  • swelling of the feet or lower legs
  • swollen glands
  • tingling of the hands and feet
  • ulceration of the skin
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • weight gain
  • yellow eyes or skin

Less common

  • Bleeding from the rectum or bloody stools
  • bloody nose
  • chest discomfort
  • confusion
  • fainting
  • irregular or slow heart rate
  • numbness or tingling in the face, arms, or legs
  • pain or discomfort in the shoulders, arms, jaw, back, or neck
  • sweating
  • swelling or puffiness of the face
  • trouble speaking, thinking, or walking

Some side effects of pazopanib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Change in hair color
  • change in taste
  • decreased weight
  • diarrhea
  • hair loss
  • lack or loss of strength
  • loss of taste
  • thinning of the hair
  • weight loss

Less common

  • Belching
  • heartburn
  • indigestion
  • stomach discomfort, upset, or pain

For Healthcare Professionals

Applies to pazopanib: oral tablet


-ALT and AST elevations occurred early in the treatment course; 92.5% of all transaminase elevations of any grade occurred in the first 18 weeks.

-Hepatic failure was the cause of death for 0.2% of RCC patients and 0.4% of STS patients.

Very common (10% or more): Increased ALT (up to 53%), increased AST (up to 53%), increased total bilirubin (up to 36%), increased alkaline phosphatase (up to 32%)

Common (1% to 10%): Abnormal hepatic function, hepatotoxicity, decreased alkaline phosphatase, increased gamma-glutamyltransferase (GGT), abnormal liver function test

Uncommon (0.1% to 1%): Jaundice, drug-induced liver injury, hepatic failure, increased hepatic enzyme

Postmarketing reports: Increased GGT


-A majority of the patients with myocardial dysfunction had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk possibly by increasing cardiac afterload.

-Cardiac dysfunction included left ventricular dysfunction, cardiac failure, and restrictive cardiomyopathy.

-Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, and thrombosis terms.

Very common (10% or more): Hypertension (up to 42%), myocardial dysfunction (up to 11%), chest pain (up to 10%)

Common (1% to 10%): Venous thromboembolic events, cardiac dysfunction, bradycardia, QT prolongation, myocardial infarction or ischemia, hot flush, flushing

Uncommon (0.1% to 1%): Torsades de pointes, congestive heart failure, fatal arterial thromboembolic events, hypertensive crisis


Very common (10% or more): Tumor pain (up to 32%), hemorrhagic events (up to 13%)

Common (1% to 10%): Edema, epistaxis, mouth ulceration, dry mouth, mucosal inflammation, gingival infection, hiccups

Uncommon (0.1% to 1%): Fatal hemorrhage, cerebral/intracranial hemorrhage, infections (with or without neutropenia), infectious peritonitis, menorrhagia, metrorrhagia, oropharyngeal pain

Postmarketing reports: Infections (with or without neutropenia)

-RCC: The most common hemorrhagic events were hematuria, epistaxis, hemoptysis, and rectal hemorrhage.

-STS: The most common hemorrhagic events were epistaxis, mouth hemorrhage, and anal hemorrhage.

-Edema events included peripheral edema, eye edema, localized edema, and face edema.


-TMA included thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).

Very common (10% or more): Increased creatinine (up to 26%), proteinuria (up to 12%)

Common (1% to 10%): Increased urea

Uncommon (0.1% to 1%): Nephrotic syndrome, thrombotic microangiopathy (TMA)

Postmarketing reports: Thrombotic microangiopathy (TMA)


Very common (10% or more): Diarrhea (up to 59%), nausea (up to 56%), vomiting (up to 33%), gastrointestinal pain (up to 23%), abdominal pain (up to 14%), mucositis (up to 12%), stomatitis (up to 11%)

Common (1% to 10%): Dyspepsia, flatulence, abdominal distension

Uncommon (0.1% to 1%): Perforation or fistula, fatal perforations, hematochezia, melena, frequent bowel movements, hematemesis, pancreatitis, peritonitis

Postmarketing reports: Pancreatitis, flatulence

Nervous system

Very common (10% or more): Fatigue (up to 65%), dysgeusia (up to 28%), headache (up to 23%), dizziness (up to 11%)

Common (1% to 10%): Insomnia, dysphonia, lethargy, paresthesia, peripheral sensory neuropathy, chills

Uncommon (0.1% to 1%): Hypoesthesia, somnolence, mucous membrane disorder, cerebral infarction, transient ischemic attack, cerebrovascular accident, ischemic stroke, posterior reversible encephalopathy syndrome/reversible posterior leukoencephalopathy syndrome (PRES/RPLS)

Postmarketing reports: PRES/RPLS

-Dysgeusia included ageusia and hypogeusia.


Common (1% to 10%): Hypothyroidism, increased thyroid stimulating hormone

Uncommon (0.1% to 1%): Abnormal thyroid function test


-Renal cell carcinoma (RCC): The most commonly observed adverse reactions (20% or more) were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting.

-Soft tissue sarcoma (STS): The most commonly observed adverse reactions (20% or more) were fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.


Very common (10% or more): Hair color changes (up to 39%), skin hypopigmentation (up to 21%), exfoliative rash (up to 18%), palmar-plantar erythrodysesthesia syndrome (up to 18%), alopecia (up to 12%), rash (up to 11%)

Common (1% to 10%): Dry skin, skin depigmentation, nail disorder, pruritus, erythema, hyperhidrosis

Uncommon (0.1% to 1%): Skin exfoliation, photosensitivity reaction, erythematous rash, skin disorder, macular rash, pruritic rash, vesicular rash, papular rash, skin ulcer


Common (1% to 10%): Hematuria


Very common (10% or more): Leukopenia (up to 44%), lymphocytopenia (up to 43%), thrombocytopenia (up to 36%), neutropenia (up to 34%), anemia (up to 27%)

Common (1% to 10%): Decreased white blood cell count

Uncommon (0.1% to 1%): Decreased platelet count


Very common (10% or more): Decreased weight (up to 48%), increased glucose (up to 45%), decreased appetite (up to 40%), increased albumin (up to 34%), decreased albumin (up to 34%), decreased phosphorus (up to 34%), decreased calcium (up to 33%), decreased sodium (up to 31%), increased potassium (up to 27%), decreased magnesium (up to 26%), anorexia (up to 22%), decreased glucose (up to 17%)

Common (1% to 10%): Increased lipase, increased amylase, dehydration, abnormal blood cholesterol


Very common (10% or more): Musculoskeletal pain (up to 23%), myalgia (up to 23%), asthenia (up to 14%)

Common (1% to 10%): Arthralgia, muscle spasms


Common (1% to 10%): Blurred vision

Uncommon (0.1% to 1%): Eyelash discoloration


Frequency not reported: Increased toxicity and mortality with other cancer therapies

-Fatal toxicities including pulmonary hemorrhage, gastrointestinal hemorrhage, and sudden death have occurred when used with other cancer agents.


Very common (10% or more): Dyspnea (up to 20%), cough (up to 17%)

Common (1% to 10%): Pneumothorax

Uncommon (0.1% to 1%): Rhinorrhea

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Votrient